Thermo Fisher Scientific Inc. (NYSE:TMO) Holdings Lifted by Invesco LLC

Invesco LLC lifted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.9% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,870 shares of the medical research company’s stock after buying an additional 204 shares during the period. Thermo Fisher Scientific makes up approximately 2.3% of Invesco LLC’s portfolio, making the stock its 8th biggest holding. Invesco LLC’s holdings in Thermo Fisher Scientific were worth $5,655,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. IFG Advisors LLC grew its position in Thermo Fisher Scientific by 3.3% during the third quarter. IFG Advisors LLC now owns 532 shares of the medical research company’s stock valued at $329,000 after buying an additional 17 shares during the period. Stonegate Investment Group LLC grew its position in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company’s stock valued at $3,531,000 after acquiring an additional 18 shares during the period. Trivant Custom Portfolio Group LLC raised its holdings in shares of Thermo Fisher Scientific by 0.4% in the 3rd quarter. Trivant Custom Portfolio Group LLC now owns 4,398 shares of the medical research company’s stock worth $2,720,000 after purchasing an additional 19 shares during the period. Axiom Advisory LLC raised its stake in shares of Thermo Fisher Scientific by 1.6% in the third quarter. Axiom Advisory LLC now owns 1,216 shares of the medical research company’s stock valued at $720,000 after buying an additional 19 shares during the period. Finally, Angeles Wealth Management LLC increased its holdings in Thermo Fisher Scientific by 0.5% in the 3rd quarter. Angeles Wealth Management LLC now owns 3,921 shares of the medical research company’s stock worth $2,425,000 after acquiring an additional 19 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Price Performance

NYSE TMO traded down $11.08 on Wednesday, reaching $573.21. 385,728 shares of the company’s stock traded hands, compared to its average volume of 1,899,792. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88. The stock has a 50-day simple moving average of $536.74 and a 200 day simple moving average of $570.35. The stock has a market cap of $219.25 billion, a PE ratio of 35.86, a P/E/G ratio of 3.82 and a beta of 0.76.

Thermo Fisher Scientific declared that its board has approved a share buyback plan on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.78%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the transaction, the chief executive officer now directly owns 111,192 shares in the company, valued at approximately $58,960,669.92. This represents a 8.25 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 34,850 shares of company stock worth $19,123,197. Insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

TMO has been the subject of a number of research reports. Bernstein Bank increased their target price on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research report on Tuesday, October 22nd. Stifel Nicolaus lowered their target price on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. Evercore ISI reduced their price target on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Scotiabank assumed coverage on Thermo Fisher Scientific in a report on Monday, December 23rd. They set a “sector perform” rating and a $605.00 price objective on the stock. Finally, Robert W. Baird decreased their price target on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $648.95.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.